Updated Phase 1 givastomig monotherapy data show an impressive 18% ORR in metastatic gastric cancer patients who had received at least two prior lines of therapy. Responses were observed over a dose ...

FMC-220 inhibits tumor cell viability across a panel of Y220C mutant cell lines and delivers tumor regression, including complete responses in p53 Y220C mutant CDX and PDX models, regardless of ...

The compelling clinical activity, durable response and acceptable tolerability profile seen with elironrasib underscore the potential of this differentiated RAS (ON) G12C-selective inhibitor, ...

Heroes of Labor began in 2012 in response to the exemplary work done by union leaders and members in the aftermath of Hurricane Sandy. These awards have been a tribute to the everyday champions of New ...

The symposium aligned closely with China’s national health priorities, and attendees engaged in in-depth discussions to explore how AI can drive the next phase of China’s public health strategy. As ...

Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced the commencement ...

ALBANY, N.Y., 22 oct. 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), une organisation leader dans la recherche, le développement et la fabrication sous contrat, a annoncé aujourd'hui que son usi ...

(Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced the launch of its pregnancy, postpartum, and menopause programs for global employers, available ...

In addition to the poster presentation, Nkarta will exhibit at booth #1801, where attendees can meet with Nkarta representatives to discuss the company’s clinical programs.

Pioneering Cost-Effective, Scalable Solutions to Combat the Global Opioid Crisis with Proprietary Air-Driven Delivery Technology ...

The CEO Corner is now accessible on the Company’s website here.

Enrollment for this Phase 3 program follows positive Phase 1/2 data demonstrating that ADX-324 achieved significant and durable suppression of prekallikrein (PKK) protein levels with a favorable ...